Intellia Halts Trial on Serious Safety Scare
A serious adverse event has forced Intellia to halt its pivotal MAGNITUDE trials for nex-z. With over 650 patients enrolled, investors are on high alert. Get the full details on this major setback and what it means for the future of NTLA.